Mounjaro May Switch On the Body’s Calorie-Burning Brown Fat, Mouse Study Suggests
Key Takeaways:
- A study in mice found that tirzepatide (Mounjaro) activates brown adipose tissue, a type of fat that specialises in using energy, and that this effect cannot be explained by reduced food intake alone.
- Unlike earlier drug-based attempts to activate brown fat, which were often hampered by side effects affecting the heart, tirzepatide shows cardiovascular benefits.
- The researchers stress that the findings come from mice and need to be confirmed in humans, but suggest they could pave the way for more personalised obesity treatment based on a person’s overall metabolic status.
Looking beyond appetite suppression
Tirzepatide has become an important treatment for obesity and related conditions such as type 2 diabetes, yet scientists are still working to understand exactly how it acts on the body. New research in mice now suggests that the drug may improve metabolism directly by activating brown adipose tissue, a form of fat that specialises in using energy rather than storing it.
According to the research team, the findings offer fresh insight into how tirzepatide works and could help shape the development of broader treatments for obesity and other metabolic disorders.
The study was led by Marion Peyrou, a Ramón y Cajal researcher at the Faculty of Biology and the Institute of Biomedicine of the University of Barcelona (IBUB), the Sant Joan de Déu Research Institute (IRSJD) and the CIBER in Physiopathology of Obesity and Nutrition (CIBEROBN).
A drug that targets two hormone receptors
Tirzepatide, the active ingredient in Mounjaro (also marketed as Zepbound), is approved for weight management in adults living with obesity, or with overweight alongside related health conditions. It is also approved for treating type 2 diabetes mellitus that is poorly controlled.
What sets tirzepatide apart from some other obesity medications is that it acts on the receptors for two hormonal factors at once: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual mechanism can lead to substantial weight loss, largely because the drug reduces how much a person eats.
For healthcare professionals supporting people who are prescribed tirzepatide and similar medicines, understanding these mechanisms is becoming increasingly relevant to everyday practice – an area explored in The College of Contemporary Health’s GLP-1RAs in Focus CPD course.
The researchers set out to establish whether tirzepatide also brings about metabolic changes that cannot simply be attributed to eating less.
How the study was designed
To answer this question, the team examined how the drug affected different fat deposits in an experimental mouse model, as this kind of detailed tissue analysis cannot readily be carried out in humans. Mice with obesity, which had been fed a high-fat diet, were treated with tirzepatide.
The researchers then compared these animals with a second group of mice that did not receive the drug but were given exactly the same amount of food. By matching food intake in this way, the scientists were able to separate the changes caused directly by tirzepatide from those that resulted from consuming fewer calories.
Tirzepatide activates brown fat
The analysis showed that tirzepatide activated brown adipose tissue. White adipose tissue mainly stores fat and tends to build up in people living with obesity, whereas brown fat specialises in using energy and “burning” the calories obtained from food.
“This activation is associated with an increased capacity to burn metabolic energy and with the production of batokines by brown adipose tissue, molecules that are beneficial for metabolism,” says Marion Peyrou.
The finding suggests that tirzepatide may influence metabolism in ways that go beyond the weight loss brought about by appetite suppression and reduced food intake.
“This drug not only reduces body weight, but also has beneficial effects on metabolism. Active brown adipose tissue ‘burns’ glucose and fat within the body, which would contribute to its positive effect not only in reducing body weight, but also in lowering blood glucose and fat levels, and improving metabolism,” the researcher points out.
Avoiding the pitfalls of earlier approaches
Scientists have long regarded brown fat activation as a potentially valuable strategy for treating obesity and other metabolic diseases. However, previous attempts to activate brown adipose tissue using drugs have frequently been unsuccessful because of unwanted side effects, particularly those affecting the heart.
“Tirzepatide, although it activates brown adipose tissue, does not have these negative effects; on the contrary, it shows cardiovascular benefits. If our findings are confirmed in humans, it would reinforce the importance of developing therapeutic strategies that not only reduce food intake but also increase energy expenditure and brown fat activation,” explains the researcher.
The results support the view that obesity treatments may be more effective when they act on several physiological processes at once, rather than focusing on appetite alone.
“This could help improve weight control and reduce associated disorders, such as type 2 diabetes and other metabolic disorders,” she adds.
Towards more personalised obesity treatment
A clearer understanding of how tirzepatide works could also influence how medicines in this class are prescribed in future.
“Identifying which patient profiles could benefit most, for example those with more compromised energy expenditure, would open the door to more personalised medicine, based not only on appetite or weight control, but also on overall metabolic status,” she emphasises.
Caution needed before applying the findings to people
The researchers are clear that because the findings come from mice, it cannot yet be assumed that tirzepatide acts in the same way in humans. Metabolism can differ considerably between the two species, as can the distribution of fat tissue and the way each responds to medications.
“As this is a study conducted on mice, we must be cautious, as there may be significant differences between species in terms of metabolism regulation, adipose tissue distribution and response to drugs. Therefore, we need more clinical evidence on the action of these drugs on fat in humans,” concludes Peyrou.
CCH insight
As research continues to reveal how dual GIP/GLP-1 receptor agonists such as tirzepatide act on the body – from appetite regulation to potential effects on energy expenditure – healthcare professionals need a confident, up-to-date understanding of these medicines to support the people in their care. The College of Contemporary Health’s GLP-1RAs in Focus CPD course offers a practical grounding in how these therapies work and how they fit into modern obesity and diabetes care.
Source: Biomedicine & Pharmacotherapy
Read More
Greater Weight Loss, More Side Effects: What GLP-1 RAs Mean for Women
Key Takeaways:
- Real-world studies show women treated with GLP-1 receptor agonists (GLP-1 RAs) report side effects such as headache, vomiting and dizziness more often than men, even though placebo-controlled trials suggest similar rates in both sexes.
- Women tend to lose more weight on GLP-1 RAs than men, while improvements in blood sugar control are comparable, possibly due to higher drug exposure, stronger suppression of food-motivated behaviours and interactions between GLP-1 signalling and oestrogen.
- The authors call for mandatory sex- and ethnicity-stratified trial reporting, more research across every stage of women’s lives, and equitable global access to genuine GLP-1 RAs, as nearly 80% of eligible adults live in low- and middle-income countries where access remains minimal.
A call to action on GLP-1 RA use in women
The second of a Series of papers presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (28 September – 2 October), and published in The Lancet Obstetrics, Gynaecology & Women’s Health, examines the wide-ranging issues surrounding GLP-1 RA use in women.
The authors, including Professor Paul Franks of Lund University and Helsingborg Hospital, Helsingborg, Sweden, and Professor Claire Meek of the Leicester Diabetes Research Centre and Leicester NIHR Biomedical Research Centre, Leicester, UK, alongside colleagues, issue a call to action to strengthen the evidence base for GLP-1 RA use in women worldwide.
The global burden of obesity among women
The prevalence of obesity is estimated to be slightly higher among women than among men, and this difference varies according to socioeconomic status. A recent analysis by the Global Burden of Disease group estimated that, in 2021, the global prevalence of overweight or obesity was 46.7% in females and 43.4% in males. Projections for 2050 rise to 60.3% and 57.4%, respectively.
This gender gap is more pronounced in low- and middle-income countries (LMICs), with the largest gaps seen in sub-Saharan Africa and south Asia. By contrast, men in high-income countries can have higher prevalence rates. The trend is likely to continue in the coming decades and is linked to socioeconomic inequalities, highlighting how broader social barriers disproportionately affect women in many regions of the world.
Why women may lose more weight on GLP-1 RAs
Weight loss with GLP-1 RAs is greater in women than in men, yet improvements in blood sugar control are comparable between the sexes. Several mechanisms could explain this greater weight-loss efficacy in women:
- Higher systemic drug exposure has been observed in women, even after adjusting for body mass.
- Women treated with GLP-1 RAs may experience enhanced suppression of food-motivated behaviours and greater inhibition of palatable food intake.
- Pre-clinical studies have highlighted possible interactions between GLP-1 signalling and oestrogen.
Side effects and weight regain
Real-world studies comparing adverse event rates in women and men treated with these medications have found a higher overall frequency of reported side effects among women, including increased rates of headache, vomiting and dizziness. This contrasts with placebo-controlled trials, which suggest similar rates in both sexes. The authors therefore stress that more studies are needed to quantify side-effect profiles in women and to develop strategies to mitigate them.
It is also well established that weight can be regained rapidly after GLP-1 RA treatment is stopped. Regaining fat without regaining additional muscle raises concerns about longer-term health and physical function in women, and further research is needed to ensure these powerful medications support women’s wellbeing over the long term.
Mental health and psychiatric safety
Trial data to date support the overall psychiatric safety profile of GLP-1 RAs, while reinforcing the importance of individualised risk assessment. Careful, routine screening for depression, anxiety and eating disorders is recommended for people of both sexes, both before treatment begins and during follow-up.
For healthcare professionals prescribing or supporting people on these medications, The College of Contemporary Health’s GLP-1RAs in Focus course offers a grounding in GLP-1 receptor agonist therapy, helping clinicians approach treatment decisions, monitoring and patient conversations with confidence.
Affordability and access in low- and middle-income countries
Independent manufacturing estimates suggest that semaglutide, for example, could be produced for less than $1 per month’s supply in oral form and $5 per month as an injection. However, recent analyses across 99 countries indicate that nearly 80% of adults who meet clinical eligibility criteria for GLP-1 RAs live in LMICs, where access remains minimal. In many of these settings, retail prices exceed $90 per month, placing treatment beyond the reach of women who rely on publicly funded care or out-of-pocket payments.
Diverse populations and polyendocrine metabolic ovarian syndrome
The paper explores multiple areas in which GLP-1 RAs affect women’s health, and highlights the need for further research in each. For example, many women with type 2 diabetes in LMICs are lean, and the BMI threshold at which type 2 diabetes begins to develop is often lower than for people of European ancestry. As a result, significant weight loss could have a more pronounced impact on these women.
Polyendocrine metabolic ovarian syndrome (PMOS; formerly polycystic ovary syndrome) affects around 12% of women worldwide, with the highest rates in the eastern Mediterranean region and south-east Asia. Although weight loss leads to various health improvements in women with PMOS, GLP-1 RAs are not generally available or centrally funded for PMOS in most healthcare systems.
Research priorities across women’s lives
The authors conclude that extensive research into GLP-1 RA use in women is needed across a range of domains, including:
- mental health and eating disorders
- contraception, fertility and polyendocrine metabolic ovarian syndrome
- optimising pre-pregnancy health
- preventing complications
- safety during pregnancy and breastfeeding
- optimising health and body composition during menopause
- optimising cardiovascular health and preventing multimorbidity
- frailty and healthy ageing
The authors’ call to action
In their call to action, the authors say:
- “Women face the highest burden of obesity and its related complications, and should have access to high-quality, equitable, multidisciplinary obesity care worldwide”
- “Sex-stratified and ethnicity-stratified reporting of clinical trials related to GLP-1 receptor agonist use should be mandatory to facilitate future meta-analyses”
- “As the main users of GLP-1 receptor agonists and incretin-based therapies, women’s care should be guided by high-quality studies assessing their treatment’s efficacy and safety, specifically in conditions affecting women (eg, before, during, and after pregnancy)”
- “Existing access pathways to GLP-1 receptor agonists disadvantage women – to maximise the treatment’s benefits, companies, health-care funders, research funders, insurers, and policy makers should promote equitable access to high-quality, genuine GLP-1 RAs for women worldwide”
The authors conclude: “Tackling the global challenges in access to GLP-1 receptor agonists provides substantial opportunities to improve women’s health internationally. However, achieving equitable access will require coordinated action to strengthen supply chains, enhance regulatory vigilance against falsified and compounded products, and embrace innovative therapies – such as oral agents – that are stable, scalable, and potentially more affordable…Advancing women-centred obesity care demands targeted research, including trials inclusive of diverse ethnic groups, women of reproductive age, and LMIC populations, alongside women-focused cost-effectiveness and implementation studies.”
CCH insight
As GLP-1 RAs become central to obesity and diabetes care, understanding how they affect different groups, including women at different life stages, is increasingly important for safe, effective prescribing. Build your knowledge with our GLP-1RAs in Focus CPD course.
Explore GLP-1RAs in Focus – Why Drugs Like Ozempic Work →
Source: European Association for the Study of Diabetes
Read More
GLP-1 Prescribing in Under-12s Has Risen 310-Fold Since 2019
Key Takeaways:
- GLP-1 prescribing for US children aged 8 to 11 living with obesity rose 310-fold between 2019 and 2026, though overall numbers remain low.
- Most of those prescribed the medicines had severe obesity (93.7 per cent) and 65.2 per cent already had an obesity-related condition.
- Children in higher-income communities were 55 per cent more likely to receive a prescription, pointing to a widening access gap.
A first national picture of GLP-1 use in younger children
New research from NYU Langone Health has produced what its authors describe as the first national overview of how glucagon-like peptide-1 (GLP-1) receptor agonists are being prescribed to children under the age of 12 who are living with obesity in the United States.
The headline finding is one of rapid acceleration from a very low base. The number of US children under 12 living with obesity who were prescribed the weight loss medicines Saxenda, Wegovy and Zepbound remained low in June 2026 – but it was 310 times higher than in 2019, the year the medicines first began to be prescribed in this group.
The study was published online in the journal Pediatrics on 4 September.
What the researchers found
Among children aged 8 to 11 who were living with obesity and did not have diabetes, the proportion prescribed a GLP-1 receptor agonist increased from 0.03 per cent in 2019 to 9.3 per cent in 2026 – a 310-fold rise across a period of seven and a half years. Over that timeframe, 20,282 children aged 8 to 11 were prescribed a GLP-1 medicine.
The researchers also compared prescribing across age groups. GLP-1 medicines were less commonly prescribed to younger children living with obesity, aged 8 to 11, than to adolescents living with obesity, aged 12 to 17, at 0.6 per cent and 0.9 per cent respectively.
That age gradient persists even though clinical guidelines permit the use of these medicines for obesity in children from the age of 8. Girls were more likely than boys to receive a prescription.
An estimated 20 per cent of children in the US are living with obesity, defined as a body mass index (BMI) above the 95th percentile for children of the same age and sex, in the absence of diabetes – a well-recognised complication of the condition.
Who is being prescribed these medicines
The clinical profile of the children receiving GLP-1 medicines suggests that prescribers are, for the most part, reserving them for those with the greatest clinical need.
Most children prescribed a GLP-1 medicine had severe obesity (93.7 per cent), meaning their BMI was substantially higher than that of almost all other children of the same age and gender. Most (65.2 per cent) were also living with at least one illness linked to obesity, such as raised cholesterol, high blood pressure or sleep apnoea.
A further quarter of the younger children living with obesity who were prescribed GLP-1s had prediabetes, placing them at high risk of developing the condition most commonly associated with obesity.
Why the researchers see this as a valuable tool
Lead investigator and obesity medicine specialist Babak J. Orandi, MD, PhD, an associate professor in the Departments of Surgery and Medicine at NYU Grossman School of Medicine, framed the findings as both a snapshot and a signal.
“Our study offers the first national overview in young children of the use of GLP-1 drugs to fight the obesity epidemic in the United States and shows that while the absolute numbers of children under the age of 12 receiving GLP-1 treatment is still low, GLP-1 use is accelerating rapidly,” said Dr Orandi. “The careful use of GLP-1s remains a valuable tool in confronting the obesity epidemic among young Americans.”
Dr Orandi noted that GLP-1 medicines can be highly effective in treating obesity and improving its metabolic complications, supporting weight loss, better blood sugar regulation and appetite suppression.
Weighing the risks of treating and of not treating
The study team was explicit that the decision facing families is not a simple choice between risk and safety.
While parents may hesitate at the prospect of their child being prescribed one of these medicines, there are also long-term risks attached to withholding treatment from young children living with obesity. Those risks include the development of chronic conditions such as diabetes, high blood pressure and liver disease in early adulthood and middle age.
For clinicians supporting families through exactly this kind of conversation, the College of Contemporary Health’s CPD short course GLP-1RAs in Practice (Prescribing and Supporting) addresses the practical side of initiating and monitoring GLP-1 therapy, including how to discuss benefits, risks and expectations with patients and their families.
An emerging gap in access
Alongside the prescribing trend itself, the study surfaced a socioeconomic pattern that the authors treat as a warning sign.
Many young children living with obesity in upper-income communities were 55 per cent more likely to be prescribed GLP-1 medicines than those who were not.
Study co-senior author Allan B. Massie, PhD, an associate professor in the Departments of Surgery and Population Health at NYU Grossman School of Medicine, said that current prescribing patterns already show the beginnings of a growing divergence between those who do and those who do not have access to the medicines.
“Physicians and health policymakers alike have a responsibility to ensure, as use of GLP-1 medications continues to rise, that all young children with obesity who need these drugs have access to them and that these valuable and sometimes costly treatments become available to more than those who have access to health insurance and can afford to visit pediatric clinics,” said Dr Massie.
The case for long-term monitoring
Dr Orandi said that long-term monitoring of children prescribed GLP-1 medicines is needed to confirm that the drugs remain both safe and effective in this age group.
Clinical trials are already under way in children living with obesity from as young as 6 years of age. Dr Orandi said these will inform and offer guidance to physicians, policymakers and parents as the use of anti-obesity medicines continues to grow.
How the study was carried out
The team drew on Epic Cosmos, a national dataset built from the electronic health records of more than 300 million American patients. The dataset covers 2,067 hospitals and 47,100 health clinics that use Epic, the largest electronic health record vendor in the US. Epic had no role in conducting the study.
Funding, authorship and disclosures
Funding support for the study was provided by NYU Langone.
Alongside Dr Orandi and Dr Massie, the NYU Langone researchers involved as co-investigators were Suhani S. Patel, MPH; Mary Jo Messito, MD; Michal A. Mankowski, PhD; and Dorry L. Segev, MD, PhD.
Dr Orandi has served on an advisory board for the pharmaceutical company Boehringer Ingelheim. Dr Segev has received consulting and speaking honoraria from Sanofi, CareDx, Moderna, AstraZeneca, Roche, Optum, OrganOx, Hansa Biopharma and Biosidus, and is a journal editor for Springer. None of these activities relate to the current Pediatrics study. NYU Langone is managing the terms and conditions of these relationships in line with its policies and procedures.
What this means for practice
The picture emerging from this study is of a treatment moving quickly from the margins towards the mainstream in a younger age group than many clinicians and families may expect – and doing so unevenly. Prescribing appears to be concentrated among children with the highest clinical need, but also among those with the greatest access to care.
For healthcare professionals, that combination raises practical questions about assessment, shared decision-making with families, monitoring over long periods, and equity of access within their own services.
CCH insight
This study was carried out in the US, where GLP-1 medications are licensed for the treatment of children with obesity from the age of 8 upwards. The picture in the UK is somewhat different, with just liraglutide and semaglutide, as Victoza and Wegovy, licensed for the treatment of obesity in under-18s, and only from the age of 12. For many people, there is an instinct to object to the use of drugs to treat obesity in children, but with severe obesity rates growing in under-18s, and children presenting with obesity-related diseases and prediabetes, it is hard to argue against the careful use of GLP-1RAs in those with greatest need, to prevent further harm to their health.
Supporting children and families through GLP-1 therapy calls for confidence in both the pharmacology and the conversation. The College of Contemporary Health’s CPD short course GLP-1RA Therapy: The Complete Programme is designed for healthcare professionals who want a structured, evidence-based grounding in initiating, monitoring and supporting GLP-1 receptor agonist treatment – including how to set realistic expectations and manage long-term follow-up.
Explore GLP-1RA Therapy: The Complete Programme →
Source: NYU Langone Health
Read More
GLP-1 Receptor Agonists: The Emerging Case for Microdosing
Key Takeaways:
- A narrative review in Cureus finds that the benefits of GLP-1 receptor agonists (GLP-1RAs) extend beyond weight reduction to cardiovascular, renal, metabolic and other outcomes.
- Its authors propose microdosing – smaller, fractional doses – as a tolerability-first approach for people who respond strongly to standard doses or who struggle with gastrointestinal side effects.
- Direct evidence is extremely limited, and microdosing remains off-label, so the authors advise caution and clinician guidance.
Why a tolerability-first conversation is gaining ground
In a recent non-systematic narrative review published in the journal Cureus, researchers summarised the current evidence on the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and discussed the possible benefits of microdosing these agents. Their central question is a practical one that clinicians increasingly face in consultation rooms: if the multisystem benefits of this drug class are real, can smaller doses preserve enough of them to keep people in treatment?
Obesity remains a substantial health concern
Obesity continues to represent a significant health concern worldwide. In the United States (US), the prevalence of generalised obesity among adults, defined as a body mass index (BMI) above 30 kg/m², and of extreme obesity, defined as a BMI above 40 kg/m², has been increasing. Childhood obesity, by contrast, is defined using age- and sex-specific BMI thresholds rather than a single fixed cut-off.
Data from a survey conducted between 2021 and 2023 indicate that 21% of children and adolescents and 40% of adults in the US were living with obesity. Those figures give a sense of the scale of the population for whom pharmacological options are now being considered, and of the pressure placed on services that support people with obesity and related conditions.
From exenatide to semaglutide: a rapidly expanding drug class
The development of GLP-1RAs has been a remarkable advancement in the treatment of obesity and diabetes. Exenatide was the first GLP-1RA approved for type 2 diabetes in 2005, and the class has since expanded to include liraglutide, dulaglutide and semaglutide.
Success, however, has brought its own difficulties. Demand for GLP-1RAs far exceeds supply, and this imbalance has contributed to high costs and significant gaps in care. The authors suggest that these pressures have encouraged greater use of medication microdosing, as people and their clinicians look for ways to stretch limited or expensive supplies of medication further.
What microdosing means in this context
The term microdosing has a specific technical origin. It originally referred to sub-pharmacologically active doses used in drug-development studies, where the intention was never therapeutic effect. The review deliberately uses the term in a different, clinical sense: smaller, fractional doses of a medication that may allow people to receive some therapeutic benefit while extending their use of the medication.
That distinction matters when interpreting the literature, because the pharmacokinetic and the clinical uses of the word describe quite different practices. It is the second, clinical meaning that the review sets out to examine.
Clinical benefits of GLP-1 receptor agonists
GLP-1RAs modulate energy intake and promote satiety through agonism of the GLP-1 receptor. They also improve glycaemic control by suppressing glucagon and stimulating insulin secretion. These two mechanisms account for much of the drug class’s original appeal in both diabetes and obesity care.
A recent umbrella review noted trends towards improvements in respiratory, renal, metabolic, endocrine and cardiovascular outcomes, as well as cognitive function, with GLP-1RAs. Taken together, these findings suggest that the benefits of the drug class may extend beyond weight reduction across multiple organ systems, which is precisely why the question of preserving those benefits at lower doses has become interesting.
Cardiovascular and renal outcomes
A meta-analysis reported that GLP-1RAs led to significant reductions in major adverse cardiovascular events (MACE) and mortality. A further meta-analysis showed that long-acting GLP-1RAs reduced MACE and improved a composite kidney outcome among people with type 2 diabetes.
An umbrella review similarly reported that GLP-1RAs were associated with improvements in body weight, glycaemic control and various renal and cardiovascular outcomes. Importantly, the certainty of evidence was lower for some of the cardiovascular and kidney outcomes, so these associations should not all be read with equal confidence.
Emerging and early-stage evidence
Beyond the established indications, the review points to areas where evidence is still at a very early stage. A case report described a 34-year-old woman with type 2, stage III lipoedema who showed improvements after 30 days of treatment with low-dose tirzepatide, a dual GIP and GLP-1 receptor agonist. A single case, however, cannot establish treatment efficacy.
A systematic review indicated that GLP-1RAs significantly improved one measure of motor function among people with Parkinson’s disease. Other motor outcomes did not improve significantly, and adverse events were more frequent. This is a useful reminder that a positive signal on one outcome measure does not amount to a demonstrated clinical benefit overall.
Current dosing regimens of GLP-1RAs
Gradual dose titration is recommended for GLP-1RAs such as liraglutide and semaglutide in order to reduce the risk of adverse gastrointestinal (GI) effects.
For obesity, semaglutide is initiated at 0.25 mg once weekly for four weeks, then increased to 0.5 mg, 1 mg and 1.7 mg once weekly for four weeks each, until reaching 2.4 mg after 16 weeks. Liraglutide, by contrast, is initiated at 0.6 mg daily for the first week, then 1.2 mg daily, 1.8 mg daily and 2.4 mg daily for one week each, reaching 3 mg daily after four weeks.
For diabetes treatment, semaglutide and liraglutide can be dosed up to 2 mg and 1.8 mg respectively, as weekly and daily subcutaneous injections. Tirzepatide has identical dosing for both type 2 diabetes and obesity: treatment starts at 2.5 mg once weekly, increases to 5 mg once weekly four weeks later, and then rises in further 2.5 mg increments every four weeks to a maximum of 15 mg weekly.
The logic of these schedules is worth noting. Titration exists because tolerability, rather than efficacy alone, governs how quickly a person can reach a therapeutic dose. Fractional dosing takes that same logic and extends it further down the dose range. Understanding titration, tolerability and shared decision-making in enough depth to have these conversations well is now core to obesity and diabetes practice, and it forms the focus of the College of Contemporary Health’s CPD short course GLP-1RA Therapy: The Complete Programme.
Tolerability and the case for microdosing
The primary limitation of long-term GLP-1RA use is adverse GI effects, including nausea, diarrhoea, constipation and vomiting. These are also among the leading causes of treatment discontinuation, which means that tolerability is not a secondary concern but a direct determinant of whether anyone benefits from treatment at all.
More severe adverse effects, including intestinal obstruction, delayed gastric emptying and biliary disease, have been variably reported, with inconsistent evidence regarding these complications. Notably, tolerability has often been found to improve over time, which suggests that fractional or lower dosing may support treatment continuity.
Microdosing as a tolerability-first framework
The authors propose microdosing as a tolerability-first framework, enabling clinicians to personalise dosing to the individual and potentially reduce barriers to treatment. They suggest it could be a valuable option for people who have exaggerated pharmacological responses to a standard dose, and for those who are highly sensitive to adverse effects.
Two important caveats accompany the proposal. First, studies on the effects of microdosing GLP-1RAs are extremely limited. Second, the established benefits of standard GLP-1RA doses cannot be assumed to persist with fractional dosing. Dose-escalation trials do suggest a strong therapeutic response in some people at submaximal doses, which is part of what makes the idea plausible, but plausibility is not proof.
What the evidence on lower doses currently shows
A prospective observational study found improvements in body weight, BMI, triglycerides, glycated haemoglobin and low-density lipoprotein cholesterol with low-dose tirzepatide among non-diabetic adults with obesity.
In addition, a pooled analysis of phase III trials assessing once-weekly semaglutide doses of 0.5 mg and 1 mg indicated improved tolerability over time and reduced sensitivity to adverse GI events with long-term exposure.
Both findings are encouraging, but the review is clear about their status: these studies provide indirect support rather than direct evidence from trials specifically designed to test a microdosing strategy.
Practical and safety considerations
The review also notes two constraints that clinicians need to weigh before considering this approach. Microdosing is an off-label approach, and fractional dosing using existing injection devices may raise sterility and safety considerations. The authors therefore recommend caution and clinician guidance before anyone begins a microdosing regimen.
Concluding remarks
Collectively, although microdosing emerged as a pharmacokinetic tool in drug development, the authors describe it as an emerging pragmatic approach in clinical practice. Alongside other treatment modalities, it may better support people in reaching their health goals and improve their quality of life.
The honest conclusion, however, is that there is limited direct evidence on microdosing GLP-1RAs. Further research is warranted to confirm whether fractional dosing helps maintain the long-term benefits that have been demonstrated at standard doses. For now, the concept is best understood as a personalised, tolerability-led hypothesis worth studying rather than a settled standard of care.
CCH insight
This paper highlights a number of questions that are being raised about the potential for microdosing of GLP-1RAs. However, it doesn’t present any new evidence or present a proposed framework or strategy for microdosing because, as it states, there is currently very little evidence. The aim of GLP-1 therapy should always be to achieve the best health outcomes for the patient, using a dose they can tolerate, and then finding the minimum dose to maintain those health benefits. The recent introduction of oral daily GLP-1RA pills should make it much easier to vary the dose, both in terms of amount and frequency, and give clinicians and patients better opportunities to find the best dose for each individual.
Conversations about titration, tolerability and dose personalisation are becoming a routine part of obesity and diabetes care, and they demand a confident grasp of both the pharmacology and the person in front of you.
The College of Contemporary Health’s CPD short course GLP-1RA Therapy: The Complete Programme is designed for healthcare professionals who want to build exactly that confidence, covering how these medicines work, how they are dosed and titrated, how adverse effects are anticipated and managed, and how to support people effectively throughout treatment.
Explore GLP-1RA Therapy: The Complete Programme →
Read More
GLP-1 Medications May Reshape Obesity Care, but Clinicians Still Have Questions
Key Takeaways:
- Staff saw injectable GLP-1 medications as a valuable middle option between behavioural support and bariatric surgery.
- Their strongest concerns centred on what happens after treatment stops, particularly weight regain and masked behavioural patterns.
- Most had learned about these medications from patients rather than through formal training.
A service preparing for a change it had not yet made
A qualitative study published in Obesity Science & Practice set out to capture something rarely documented: what healthcare professionals think about injectable GLP-1 medications before their service begins prescribing them. The researchers interviewed staff at a United Kingdom Tier 3 weight management service that had applications for approval in place but was not yet prescribing, giving an unusually clean view of expectations, hopes and anxieties uncoloured by direct prescribing experience.
The timing matters because these medications are moving quickly into routine obesity care. One in eight people worldwide lives with obesity, a scale that demands sustained attention from health authorities. In England, weight management is organised across four tiers, running from population-level prevention and lifestyle services through to specialist multidisciplinary care and bariatric surgery. Injectable GLP-1 medications, including semaglutide and tirzepatide (a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist), are increasingly built into these pathways. Semaglutide is recommended for eligible patients within specialist services, while tirzepatide can also be prescribed in NHS primary care.
How the study was carried out
Participants were recruited from a Tier 3 service in England providing interpersonal nutritional advice and behavioural support to people with a body mass index above 40 kg/m², or between 35 and 39.9 kg/m² alongside a weight-related comorbidity.
Interviews took place between 20 June and 19 July 2024. Eligible participants were behavioural change advisors or nutrition advisors, and importantly, none of them held prescribing privileges. Staff were invited by email and completed an information sheet, an electronic consent form, a demographic questionnaire and an interview-date selection.
The research team developed a semi-structured interview schedule, refining it after a pilot interview. Questions covered knowledge of semaglutide, perceived benefits, concerns, possible psychological consequences, long-term outcomes, service integration and information needs. Interviews were audio-recorded and transcribed verbatim, then analysed using Braun and Clarke’s six-stage reflexive thematic analysis. Transcripts were read repeatedly and coded in NVivo 14, with preliminary themes developed, discussed, revised, mapped, defined and named. Analysis was predominantly inductive, with a deductive element used to group themes according to the research questions, and the dataset was interpreted through a constructivist lens.
The recruitment email reached 17 healthcare professionals. Thirteen expressed interest and 11 completed interviews, comprising six nutrition advisors and five behavioural change advisors. Interviews ran from 34 to 62 minutes, with a mean of 46 minutes. Sample size was guided by information power rather than a fixed target. Thirteen themes emerged, organised into four clusters: knowledge and information needs, perceived benefits, concerns, and service provision considerations.
Learning from patients rather than from training
One of the more striking findings concerns where knowledge was coming from. Participants had mainly learned about injectable GLP-1 medications through patients who had purchased them privately. Most did not feel confident in their current understanding, reported little formal training, and often sought out information independently, though lack of time limited how far they could go.
That said, the baseline was not zero. All participants knew the medications could facilitate weight loss, and most recognised appetite suppression as an important mechanism, although understanding of how the drugs work varied considerably. A few had deeper knowledge of semaglutide’s physiological effects. Gastrointestinal effects were widely mentioned, including nausea, constipation and diarrhoea.
It is a gap that structured continuing professional development is well placed to close. CCH’s GLP-1RAs in Focus short course was built for professionals in exactly this position, including non-prescribers supporting people on GLP-1RA pathways who want a working grasp of the underlying physiology and pharmacology rather than a patchwork assembled from patient conversations.
Seen as a middle path, not a shortcut
Most participants held positive views and regarded injectable GLP-1 medications as a useful weight-loss tool. Several felt that early weight loss could boost patients’ confidence in their own ability to lose weight, and in turn encourage greater engagement with behavioural support.
Many framed the medications as a valuable middle ground between behavioural support and bariatric surgery, particularly for people with complex needs or those who did not want surgery. At the same time, participants were clear that the drugs were not a substitute for a patient’s own efforts. Where lifestyle change alone was achievable, it was generally the preferred route, partly because it could help people feel more in control of their own progress.
Concerns clustered around what happens next
The dominant concern was not the treatment period itself but what follows it. Most participants worried about weight regain after discontinuation, particularly where behavioural changes had not become established during treatment.
Closely linked to this was a worry about masking. Participants feared that appetite suppression could obscure emotional eating, stress eating, unhelpful habits and other behavioural patterns, making it harder to tell which changes were driven by the medication and which by behavioural support. There was also concern that successful weight loss could create a false sense of security, reduce engagement with lifestyle advice, or foster reliance on medication.
Some participants raised possible mental health risks, including disordered eating or worsening difficulties among people with eating disorders, psychological trauma or a history of self-harm. It is worth being precise here: these were concerns held by participants rather than harms they had observed, and the authors noted that current evidence does not support a causal relationship between GLP-1 medications and suicidal or self-injurious thoughts or actions.
Where behavioural support should sit in the pathway
Many participants favoured offering behavioural and lifestyle support before prescribing begins, giving time to understand individual needs and to manage expectations about what the medication can and cannot do. Almost all supported providing that help alongside treatment, though views differed on how often and for how long.
Some also argued for support during dose reduction and for a few months after treatment ends, precisely because of the regain risk they had identified. The introduction of GLP-1 prescribing into their own service was viewed by some as experimental and as a learning process, and participants anticipated that their professional roles and responsibilities would shift as a result.
What this study cannot tell us
The authors were candid about the limits. The study included 11 professionals from a single Tier 3 service that had not yet started prescribing injectable GLP-1 medications, so the findings may not generalise to other services or to professionals with direct prescribing experience. The interviewer also worked within the same service, which may have shaped how freely participants expressed their views.
What it means for practice
Taken together, the picture is of a workforce that is broadly positive about injectable GLP-1 medications and sees a clear clinical niche for them, but that is thinking hard about continuity of care. The concerns raised, weight regain after discontinuation, reduced engagement with behavioural support, masked behavioural patterns and possible mental health risks, are perceived rather than demonstrated harms, but they point to real design questions for services.
The authors conclude that further research is needed on combining injectable GLP-1 medications with interpersonal behavioural support, and on how that integration can best sustain patients over time. In the meantime, the most actionable finding may be the simplest one: the staff closest to patients wanted better information and had few structured routes to get it.
CCH insight
Tier 3 specialist weight management services provide care for patients with obesity with the greatest need, so it is vital that staff are well informed about GLP-1 medications. Although this study was published earlier this year, the interviews it is describing took place in June/July 2024, when the NHS was still in the early stages of rolling out its Wegovy treatment programme for Tier 3 weight management, and at a time the drug was still in short supply. Therefore it is understandable there was a lack of knowledge of GLP-1RAs amongst staff at that time. Unfortunately, despite the huge amount of evidence for the safety and benefits of these drugs, there still seems to be scepticism amongst many health professionals today about providing pharmacotherapy for obesity.
This study lands on something many services will recognise: the staff supporting people on GLP-1RA pathways are often the least formally trained in how these medications work, and the anxiety sits not in the prescription itself but in the months that follow it.
GLP-1RA Therapy: The Complete Programme (Ozempic, Wegovy & Mounjaro) is built around that full sequence, covering the science, safe prescribing and the long-term care that protects the result, from nutrition and lean mass through to plateaus and when to refer. Seven CPD hours, three Certificates of Completion, and the CCH Advanced Certificate in GLP-1RA Therapy on passing the capstone. Open to prescribers and non-prescribers alike.
Explore GLP-1RA Therapy: The Complete Programme →
Read More
Surgery Plus Medication Outperforms Surgery Alone in Young People
Key Takeaways:
- Young people who restarted obesity medication a median of one month after sleeve gastrectomy lost more weight at 12 months than those who had surgery alone.
- Improvements in eating behaviours, including hunger scores, were significantly greater in the early reinitiation group.
- Rates of postoperative complications, readmissions, emergency department visits and reoperations did not differ between the two groups.
Combining pharmacotherapy with surgery in adolescent obesity care
Restarting obesity medication, including glucagon-like peptide-1 (GLP-1) receptor agonists, shortly after sleeve gastrectomy is associated with greater weight loss at one year than surgery alone in adolescents, according to a research letter published online on 22 July in JAMA Surgery.
The finding speaks to a question that has become increasingly pressing as both metabolic and bariatric surgery and highly effective obesity pharmacotherapy have become available to younger patients: whether the two should be sequenced, or used together.
What the researchers set out to examine
Dr Alaina P. Vidmar, of Children’s Hospital Los Angeles, and colleagues evaluated the 12-month safety, weight trajectory and eating behaviour outcomes associated with early reinitiation of obesity medication following metabolic and bariatric surgery.
The analysis included 99 young people aged 7–20 who underwent sleeve gastrectomy between November 2023 and February 2026.
Half the cohort restarted medication within a month of surgery
Of the 99 young people in the cohort, 53 reinitiated obesity medication, with a median time to reinitiation of 1.0 month.
Among those who restarted treatment, most resumed the same class of medication they had been prescribed before surgery. Postoperative regimens were nonetheless generally consolidated, with fewer young people requiring multiagent therapy after their operation than before it.
Weight trajectories diverged after the six-month mark
Through the first six months, the two groups experienced similar early postoperative weight loss.
The picture changed by the end of the first year. The early reinitiation group achieved a greater mean reduction in body mass index (BMI) percentage at 12 months than the group who had surgery alone, at −29.3% versus −25.5%. The same pattern held for excess BMI loss percentage, at −53.6% versus −45.7%.
Eating behaviours improved more with combined treatment
Improvements in eating behaviours were significantly greater in the early reinitiation group at 12 months than in the surgery-only group. Median hunger scores on the Adult Eating Behaviour Questionnaire, for example, fell by 3.5 points in the early reinitiation group, compared with a rise of 0.2 points among those treated with surgery alone.
This behavioural dimension is a reminder that appetite regulation after surgery is not a fixed quantity, and that the interaction between pharmacological and surgical mechanisms is an area where prescribing clinicians increasingly need structured, up-to-date grounding. The College of Contemporary Health addresses precisely this territory in its GLP-1RA Complete Programme, which covers the pharmacology, patient selection, monitoring and behavioural support that underpin safe long-term use of these agents.
Safety outcomes were comparable between the groups
There was no difference between the groups in postoperative complications, including biliary events requiring cholecystectomy, readmissions, emergency department visits and reoperations.
A lifespan view of severe obesity
The authors frame the results as support for treating severe obesity in young people as a chronic condition requiring more than one modality.
“Bariatric surgery is the most durable and effective treatment for severe obesity, but for youth with severe disease, we need a multimodal approach, which means combining medication and surgery over the lifespan,” Vidmar said in a statement.
CCH insight
For clinicians supporting young people through and beyond metabolic and bariatric surgery, findings like these shift the practical question from whether to prescribe to when, what and for how long. Confidence with GLP-1 receptor agonists, and with the behavioural and monitoring work that surrounds them, is becoming a core competency rather than a specialist interest.
The College of Contemporary Health’s GLP-1RA Complete Programme is designed for healthcare professionals who want that grounding: mechanisms of action and the wider incretin landscape, patient selection and contraindications, dose escalation and adverse effect management, and the behaviour change support that helps people sustain outcomes over time. It is CPD-accredited and studied entirely online, so it fits around clinical commitments.
Explore the GLP-1RA Complete Programme →
Read More
Obesity Medication Significantly Reduces Risk of Infections and Serious Cardiovascular Events
Key Takeaways:
- Tirzepatide cut the combined risk of heart attack, stroke and death by around a third compared with sitagliptin over one year.
- Hospital admissions for infection fell by 36 per cent, and infection-related deaths by 60 per cent.
- Real-world insurance data offers evidence on GLP-1 medications that clinical trials have not yet produced.
A large real-world comparison of two diabetes medicines
People living with type 2 diabetes and obesity may gain substantially more than improved blood glucose control from treatment with tirzepatide. New research indicates that the medication, marketed as Mounjaro, is associated with roughly a one-third reduction in the risk of heart attack and a similar reduction in hospital admissions for infection, when compared with a conventional diabetes medication.
The findings come from researchers at the Technical University of Munich (TUM) and Harvard Medical School, who used health insurance data to examine how the drug performs outside the tightly controlled conditions of a clinical trial. Their study has been published in The BMJ.
What the researchers did
The team analysed a large dataset drawn from United States health insurance providers, comparing outcomes among people treated with tirzepatide against those treated with sitagliptin. Sitagliptin was chosen deliberately: it is a diabetes medication regarded as neutral with respect to cardiovascular outcomes, which makes it a useful yardstick for isolating any additional benefit attributable to tirzepatide.
That design matters. Rather than measuring tirzepatide against a placebo, the researchers set it against an established, widely used treatment that people with type 2 diabetes might realistically be prescribed instead – a comparison closer to the decisions clinicians and patients actually face.
Cardiovascular events reduced by around a third
The results pointed to clear advantages for the GLP-1 medication, a class that has drawn considerable public attention in recent years for its effects on weight.
After one year, 4.4 per cent of people treated with the comparator drug had experienced a heart attack or a stroke, or had died. Among those treated with tirzepatide, the figure was 2.9 per cent. The gap corresponds to a relative risk reduction of approximately one third.
Expressed in absolute terms, the difference of roughly 1.5 percentage points over a single year is meaningful in a population already carrying elevated cardiovascular risk from both type 2 diabetes and obesity.
Fewer hospital admissions for infection
The second set of findings was less anticipated. Significantly fewer people treated with tirzepatide were admitted to hospital with infections, with the associated risk reduced by 36 per cent. The risk of dying from an infection was reduced by as much as 60 per cent.
“The data on infections surprised us because the findings were so striking,” says Dr. Nils Krüger, first author of the study and a resident physician in the Department of Cardiovascular Diseases at TUM University Hospital. “Previous studies have suggested that people treated with GLP-1 agonists are less likely to be hospitalized for infections and less likely to die from them.”
In other words, the direction of the signal was not new – but its size was.
Why obesity may affect the immune response
According to Dr Krüger, the reasons behind the association are not yet fully understood. One plausible explanation lies in the relationship between excess adiposity and chronic inflammation.
“There is evidence that obesity promotes inflammatory processes in the body, which may in turn impair immune function. The exact mechanisms and whether this apparent benefit would also occur without weight loss now need to be investigated.”
That final point is the crux of the open question. If the protective effect is driven principally by weight loss, it would be expected to accompany any effective weight management intervention. If it persists independently of weight change, it would suggest something about the medication’s action on inflammatory or immune pathways that has yet to be characterised. Distinguishing between those possibilities will require dedicated research.
Building healthcare professionals’ understanding of how medications in this class work – and how to interpret emerging evidence about their wider effects – is the focus of professional training such as the College of Contemporary Health’s GLP-1RAs in Focus, a CPD-accredited online short course.
How routine clinical data complements traditional trials
In Dr Krüger’s view, studies that draw on routine clinical data to compare the effects of medications are an important complement to conventional clinical trials. This is particularly true for GLP-1 agonists such as tirzepatide and semaglutide, sold as Mounjaro, Wegovy and Ozempic.
Because these medications have been on the market for a relatively short time, only a small number of large-scale studies have examined the full range of effects associated with the class. Medical societies and regulatory authorities need more research of this kind to underpin their recommendations.
There is also a practical problem that database research helps to solve. “Clinical trials are increasingly comparing active ingredients with one another,” says Dr Krüger. Regulatory authorities, however, often also require comparisons against the established standard of care rather than against another modern drug – a requirement that raises an ethical difficulty if it means assigning trial participants to older treatment while withholding a therapy that may benefit them.
“Database studies that are benchmarked against the results of traditional clinical trials can fill this gap without actually withholding potentially beneficial therapies such as GLP-1 agonists from study participants,” he says.
What this means for clinical decision-making
By enabling a direct comparison with standard diabetes treatment, Dr Krüger hopes the study will provide an additional tool to support decision-making by patients and their physicians.
For healthcare professionals supporting people who live with both type 2 diabetes and obesity, the practical implication is that the conversation about tirzepatide may extend well beyond glycaemic control and weight. Cardiovascular protection and, potentially, resilience to serious infection now form part of the evidence that can be weighed when treatment options are discussed.
As with all analyses of routinely collected data, the findings describe an association rather than establishing cause and effect, and the mechanisms behind the infection results remain to be confirmed. What the study adds is real-world evidence at a scale, and against a comparator, that trials have not yet delivered.
CCH insight
It seems that every week we learn of a new benefit attributable to GLP-1 based medications – this time a significant reduction in infections in patients taking tirzepatide. In view of the links between central adiposity and vitamin D deficiency, and the fact that vitamin D plays an important role immunity, it would be interesting to know if these results might be linked to improved vitamin D status as a result of abdominal fat loss.
Findings like these show how quickly the evidence base around GLP-1 medications is expanding, and how much rests on the professionals discussing these treatments understanding both how they work and how to appraise new data with confidence. CCH’s GLP-1RAs in Focus – Why Drugs Like Ozempic Work CPD short course (2 CPD hours, fully online, CPD-accredited) gives healthcare professionals, whether or not they prescribe, a clear grounding in the science behind medications such as tirzepatide, where they fit in treatment pathways, and how to weigh emerging evidence critically.
Read More
Weight Bias at Work: What New GLP-1 Research Reveals About Women’s Employment Prospects
Key Takeaways:
- Women who were unemployed when they started GLP-1 medications saw their employment rate rise by nearly 27 percentage points over 18 months, according to a 2026 NBER working paper.
- The gains appeared only among women entering the workforce – those already employed saw no rise in pay or promotion, pointing to perception rather than capability.
- The findings echo long-standing evidence on the financial cost of weight bias, from documented pay gaps to hiring professionals’ judgements based on photographs alone.
A new way to measure an old problem
For years, economists have documented what they call the “obesity penalty” – the social and financial disadvantages people can face because of their weight. It has been a difficult phenomenon to measure cleanly, because the factors that shape someone’s body weight also tend to shape their income, health and opportunities.
The rapid uptake of GLP-1 medications has given researchers something closer to a natural experiment. When large numbers of people begin treatment within a short window, and others who want the same treatment have not yet been able to start, it becomes possible to compare two otherwise similar groups and observe what changes.
That is the approach taken in a 2026 working paper published by the National Bureau of Economic Research, in which Harvard economist Rebecca Diamond examined what happened to women’s employment after they began taking GLP-1 medications.
What the researchers did
Diamond looked at survey data from around 15,000 people. She compared women who had started taking GLP-1 medications with similar women who wanted to take them but had not yet started. The two groups were matched on factors including income, race, body mass index and overall health, so that the comparison was not simply between people in very different circumstances to begin with.
The design matters. Because the comparison group consisted of women who also wanted the medications, the study is less vulnerable to the criticism that people who seek treatment are systematically different in motivation from those who do not.
The result that stands out
Among women who were unemployed at the point they began treatment, the employment rate rose by nearly 27 percentage points over the following 18 months, compared with the matched group who had not yet started.
To put that figure in context, it is a larger gap than the difference in employment between American women with a high school diploma and those holding a university degree. In other words, an 18-month change in body weight was associated with a bigger shift in employment than several years of formal education.
The research does not suggest that losing weight made these women more intelligent, more capable or better qualified for work. Nothing about their skills, experience or credentials changed. What the study raises is a different and more uncomfortable question: whether a change in appearance alters how women are perceived by employers.
Changes beyond the workplace
The effects were not confined to employment. The study also found that single women taking GLP-1 medications were nearly 29 percentage points more likely to get married or move in with a partner than similar women who had not started treatment.
Taken together, the employment and partnership findings describe something broader than a labour market effect. They describe a shift in social response.
The financial cost of weight bias
GLP-1 medications have moved quickly into the mainstream. In 2026, 11% of US adults said they were currently taking one to lose weight, up from just 3% in 2024, according to Gallup.
But the question of how weight shapes women’s working lives long predates the current wave of prescribing. Research was already pointing in this direction well before GLP-1 medications entered the cultural conversation.
What hiring professionals saw
A report from Fairygodboss, an employer review site for women, offered a particularly troubling look at how appearance can shape hiring decisions. In one study, hiring professionals were shown images of women with different body types and asked to evaluate them.
The woman pictured at the highest body weight was judged far more harshly than the others. Twenty percent of respondents described her as “lazy”, a label applied less frequently to every other woman pictured. Just 18% said she appeared to have leadership potential, while 21% described her as “unprofessional”.
These are judgements made on the basis of a photograph alone, with no information about experience, qualifications or performance.
Earnings gaps documented long before GLP-1 medications arrived
The pay data tells a similar story. In 2011, the Federal Reserve Bank of St Louis cited research finding that white women living with overweight earned about 4.5% less than white women whose BMI fell within what researchers classified as the normal range. White women living with obesity earned nearly 12% less.
Two caveats are important here. Those figures were specific to white women and do not apply to everyone. They also say nothing about anyone’s value, ability or contribution. What they suggest is that weight-related bias was already showing up in some women’s pay long before GLP-1 medications became widely available.
When appearance pays
The argument that appearance carries an economic premium is not new, and it is sometimes made bluntly. Codie Sanchez, CEO and founder of Contrarian Thinking, has said that women who wear makeup to work earn about 30% more on average than women who do not.
“Pretty privilege is very real,” she said on an episode of The Burnouts Podcast. “And you can either say ‘That’s not fair, so I’m not doing it.’ or you can win.”
Sanchez acknowledged that the advantage is unfair, but argued that women should use it rather than ignore it. “If it’s going to make me more money to paint my face, clown me up,” she said.
Diamond’s findings suggest weight bias may operate along similar lines. The women who benefited most were those seeking to enter the workforce, where first impressions carry disproportionate weight and where an employer’s judgement is formed quickly and on limited information. For women already in a job, whose managers had direct evidence of their performance, the effect disappeared.
Why this matters in clinical practice
For healthcare professionals, findings like these complicate the consultation room. People starting GLP-1 medications may be motivated by clinical goals, social goals, economic goals, or some mixture of all three, and those motivations shape expectations, adherence and how someone responds if treatment is paused or stopped.
Understanding the pharmacology well enough to have that conversation credibly is increasingly part of everyday practice rather than a specialist concern. Building that grounding is the focus of professional training such as the College of Contemporary Health’s GLP-1RAs in Focus – Why Drugs Like Ozempic Work, a CPD-accredited online short course covering GLP-1 physiology and pharmacology for prescribers and non-prescribers alike.
An uncomfortable conclusion
Losing weight does not make a person more intelligent, more capable, harder working or better qualified for a job. But it may change how other people perceive them.
That is precisely what makes Diamond’s findings difficult to sit with. If some women gain access to more opportunities after losing weight while their underlying abilities remain exactly the same, then the economic benefit is not really a benefit at all. It is a measure of how heavily appearance still shapes the way women are perceived and treated – and of how much value has been withheld from them beforehand.
The medication changed the response. It did not change the woman.
CCH insight
Findings like these are a reminder that GLP-1 medications carry social and economic weight as well as clinical effect – and that patients arrive at the consultation with motivations shaped by far more than a treatment target. CCH’s GLP-1RAs in Focus – Why Drugs Like Ozempic Work CPD short course (2 CPD hours, fully online, CPD-accredited) builds the foundation in GLP-1 physiology and pharmacology that healthcare professionals need to explain the science clearly, set realistic expectations and contribute confidently to treatment discussions, whether or not they prescribe.
Read More
Sensing, Liking and Wanting: Why Food Feels Different on GLP-1RAs
Key Takeaways:
- A Frontiers in Nutrition review finds that altered eating experience on GLP-1 receptor agonists (GLP-1RAs) reflects changes in food reward rather than impaired taste function.
- The authors separate three processes: sensing food, liking it, and wanting it.
- The evidence is heterogeneous and largely observational, so the framework is a conceptual model, not proof of causality.
Why reports of “taste changes” may not be about taste at all
Some people taking GLP-1RAs report that their favourite foods become less enjoyable or tempting, without this necessarily reflecting impaired basic taste function. That distinction sits at the centre of a recent review published in the journal Frontiers in Nutrition, in which the authors conducted a structured narrative review of current evidence on how glucagon-like peptide-1 receptor agonists influence sensory perception, food enjoyment and food motivation, using a sensory-liking-wanting framework.
Obesity is a chronic, progressive metabolic disease with growing global prevalence, which increases the demand for effective long-term treatment options. GLP-1RAs are widely used in obesity treatment because they enhance satiety, delay gastric emptying, reduce energy intake and support meaningful weight loss. Alongside those effects, some people also report that food tastes different, feels less enjoyable, or no longer seems tempting. These experiences are often described as “taste changes”, but the review argues that they may reflect several biological processes rather than a single taste disorder. Further research is needed to understand these mechanisms and to improve nutritional care during treatment.
Looking beyond appetite suppression
GLP-1RAs have changed the way obesity is managed by reducing energy intake and supporting meaningful weight loss. Growing clinical experience, however, shows that their effects extend beyond a simple reduction in hunger.
Some people describe food tasting different, reduced pleasure in eating, or lower cravings for high-calorie foods. The review suggests that these experiences should not be treated as simple taste disturbances, but as a combination of three components related to eating behaviour: sensory perception, liking and wanting.
The three components of eating behaviour
Eating begins with sensory perception, which includes detecting taste, smell and food texture. This stage determines how food is initially recognised.
The second component is liking, defined as the subjective pleasure or hedonic value associated with eating. It is influenced by flavour, prior experience, context, cognitive factors and physiological state.
The third component, wanting, describes the motivation or craving to seek out and consume food. Separating these components helps explain why reports of “taste changes” may in fact reflect different biological processes.
How GLP-1RAs may influence food reward and the eating experience
The review sets out how GLP-1RAs may influence eating behaviour through interconnected biological pathways rather than by directly changing taste. Preclinical studies indicate that endogenous glucagon-like peptide-1 (GLP-1) is produced by some mammalian taste bud cells and may modulate taste signalling. Those findings do not establish that GLP-1RA treatment directly alters taste in humans, and the limited human studies available have produced inconsistent results.
Taste signals are integrated in the nucleus of the solitary tract (NTS) before reaching brain regions involved in appetite and reward. Human studies have associated GLP-1RA treatment with reduced craving and weaker neural responses to calorie-dense food cues in some participants. Those findings are more consistent with altered food valuation and motivation than with impaired basic taste.
Gastrointestinal effects, including nausea and early satiety, may also reduce the pleasure of eating, which makes it difficult to distinguish altered food reward from genuine changes in taste perception.
What the clinical evidence does and does not show
Randomised controlled trials usually focus on body weight and metabolic outcomes. Eating-related experiences are rarely included as prespecified measures and are more often captured sporadically as adverse events.
Patient-reported outcome questionnaires may provide a more sensitive window into changes in food enjoyment and preference, but assessment methods vary considerably between studies. Real-world evidence presents additional challenges, as reports of “taste alterations” may encompass several distinct sensations, including olfactory changes, dry mouth, gastrointestinal discomfort and other symptoms that are difficult to distinguish clinically.
Spontaneous reporting databases can identify safety signals but cannot establish incidence or risk. Cohort studies, by contrast, provide better-defined populations and follow-up, yet remain vulnerable to subjective reporting and confounding.
Because this was a narrative review rather than a systematic review or meta-analysis, the authors did not conduct a formal risk-of-bias assessment.
A framework for understanding what people report
According to the review, alterations in the eating experience during GLP-1RA treatment should not be regarded solely as a biological phenomenon, but understood as the interaction between different processes.
Peripheral taste pathways, brainstem integration, central reward networks, interoceptive state and learned behaviour may all contribute. Their relative importance may differ between individuals and across treatment stages. A person’s report of a “taste change” may therefore not correspond to a clinically defined gustatory disorder.
The authors also note that alternative explanations should be considered when interpreting eating-related changes, including nausea, delayed gastric emptying, altered satiety, behavioural adaptation and medication adherence.
The framework additionally accommodates limited treatment response, persistent appetite, weight regain after treatment withdrawal or interruption, and rare atypical or paradoxical responses.
Clinical relevance and a possible stage-dependent pattern
The review highlights that reported changes in eating experience should not automatically be classified as taste abnormalities. Healthcare professionals may find it useful to establish whether a person is describing altered taste perception, reduced satisfaction from eating, or diminished interest in food, as these experiences can reflect distinct processes. Distinguishing between them well depends on the quality of the conversation in the consultation, and supporting people through the eating-related changes that accompany GLP-1RA treatment is the focus of professional training such as the College of Contemporary Health’s GLP-1RAs in Practice: Supporting Patients During Treatment, a CPD-accredited online short course.
The authors present these points as translational implications rather than formal clinical recommendations. They also propose a stage-dependent pattern in which these experiences may change over time.
Early in treatment, gastrointestinal discomfort and enhanced satiety may reduce the appeal of food, whereas later stages may involve a more persistent reduction in motivation towards highly rewarding foods in some individuals.
Why this matters for nutrition and obesity management
The proposed sensory-liking-wanting framework has practical implications for obesity treatment and nutritional counselling. Understanding whether someone is experiencing altered sensory perception, reduced enjoyment of food, or lower motivation towards food may support more individualised dietary guidance and improve communication between people receiving treatment and the professionals caring for them.
The review also highlights that the existing body of evidence is heterogeneous, owing to differences in endpoint definitions, measurement methods, populations, drugs, doses and follow-up periods. Much of the human evidence is observational, secondary or exploratory, and many studies were not designed to separate sensory function from liking and wanting. Current findings are therefore better interpreted as a conceptual framework for organising available evidence than as proof of a single causal pathway.
Future studies using standardised, multimodal assessments and longer follow-up may help clarify how these eating-related changes influence food preferences, dietary behaviour, long-term weight management and treatment adherence.
Conclusion
The review concludes that altered eating experiences during GLP-1RA therapy are more consistent with changes in food reward, hedonic evaluation and motivational drive than with a uniform impairment of taste function, although modulation of peripheral taste pathways may contribute in some cases.
Current evidence supports interpreting reported “taste changes” within a sensory-liking-wanting framework that distinguishes sensory perception from food enjoyment and craving. Because responses vary between individuals and the available evidence remains heterogeneous, the proposed framework should be considered a conceptual model rather than definitive proof of causality.
Longitudinal, multimodal human studies measuring sensory function, hedonic response, motivational drive and state-related symptoms in parallel are needed to clarify these effects and their implications for nutrition, dietary behaviour, treatment adherence and long-term obesity management.
CCH insight:
When someone says food no longer tastes right on a GLP-1RA, the clinically useful question is which part of eating has changed: the sensing, the liking or the wanting. Each points towards different advice, and each can shift as treatment progresses. CCH’s GLP-1RAs in Practice: Supporting Patients During Treatment CPD short course (2 CPD hours, fully online, CPD-accredited) equips healthcare professionals to have exactly those conversations – recognising what people are really describing, adapting dietary and nutritional support through the course of treatment, and monitoring for the changes that matter.
Explore GLP-1RAs in Practice: Supporting Patients During Treatment →
Read More
GLP-1 Therapies Linked to Lower Fragility Fracture Risk in Adults Living With Type 2 Diabetes
Key Takeaways:
- Adults aged 50 and over living with type 2 diabetes who started a GLP-1 receptor agonist had a 21% lower three-year risk of fragility fracture than those starting a DPP-4 inhibitor (HR 0.79).
- Reductions were strongest for vertebral (HR 0.68) and hip or femur fractures (HR 0.70), and appeared independent of changes in BMI and HbA1c – pointing to a possible direct skeletal effect.
- The findings do not extend to younger people using GLP-1 medications for weight management alone, or to those with osteoporosis; among adults without diabetes, fracture risk was higher (HR 1.13).
A large-scale look at bone health during GLP-1 treatment
Initiating a GLP-1 receptor agonist for type 2 diabetes was associated with a lower risk of fragility fractures in adults aged 50 and over, including fractures of the hip and spine, according to a large target trial emulation study published in JAMA Network Open.
Over three years of follow-up, adults who newly started a GLP-1 medication had a 21% lower risk of fragility fracture than those who newly started a DPP-4 inhibitor (HR 0.79, 95% CI 0.76–0.83), reported Christopher Hamad, MD, of the University of California Los Angeles, and colleagues.
The authors were careful to frame the size of the effect in context rather than overstate it.
“Although the absolute risk reduction at 3 years was modest (0.79%), this magnitude is clinically relevant given a baseline 3-year major osteoporotic fracture risk of approximately 3% to 4% in comparable populations and the substantial morbidity and mortality associated with hip and vertebral fractures,” the authors wrote.
Why a modest absolute reduction still matters
The clinical weight of these numbers rests on how serious the events being prevented are. Hip fractures, for example, are associated with one-year mortality rates of up to 25% in women and up to 36% in men.
Given the potential for such severe outcomes, Hamad’s group emphasised that even modest absolute reductions in fragility fractures – which stem from low-energy trauma, such as a fall from standing height – can prevent a meaningful number of events at population level.
The findings build on several smaller observational studies in people living with diabetes that have similarly linked the use of GLP-1 medications such as semaglutide (Ozempic, Wegovy) to a reduced fracture risk. Hamad’s team noted that their analysis drew on the largest dataset assembled on this question to date.
Which fractures showed the strongest signal
The protective association was most pronounced at precisely the sites that carry the highest morbidity and mortality:
- Vertebral fractures: HR 0.68, 95% CI 0.63–0.73
- Hip or femur fractures: HR 0.70, 95% CI 0.63–0.79
- Rib fractures: HR 0.83, 95% CI 0.77–0.91
No significant associations were identified for fractures of the distal radius or ulna, or of the proximal humerus.
Weight loss, glycaemic control and the question of a direct skeletal effect
One of the more striking elements of the analysis concerns the mechanism. Mediation analyses indicated that the associations were independent of changes in BMI and HbA1c, a pattern consistent with a potential direct skeletal effect of GLP-1 medications.
That matters because weight loss itself is associated with reduced bone mineral density and a higher fracture risk – a relationship reflected in the study’s own data, which found that cumulative BMI loss was tied to a 2% increase in fracture risk. In other words, the expected consequence of the weight reduction these medications produce would be a rise in fracture risk, not a fall.
“Yet, GLP-1 RA [receptor agonist] use was associated with lower fracture risk despite these changes, suggesting that potential direct skeletal effects may outweigh the adverse consequences of weight loss,” the authors wrote.
Reassessing the assumption of neutral skeletal effects
Current American Diabetes Association Standards of Care classify GLP-1 medications as having neutral effects on the skeleton. The researchers argued that their results suggest this assumption warrants reevaluation.
They also acknowledged the limits of what an observational design can establish, noting that the findings could still reflect unmeasured factors such as improved balance or greater physical activity among people taking these medications. Making sense of evidence like this – and of the mechanistic arguments used to interpret it – is the focus of professional training such as the College of Contemporary Health’s GLP-1RAs in Focus, a CPD-accredited online short course that grounds healthcare professionals in how these medications act on the body.
How the study was conducted
For this comparative effectiveness study, the researchers drew data from the TriNetX Research Network, analysing 66,803 matched pairs, or 133,606 people in total, aged between 50 and 90 years.
Mean age was approximately 63 years, roughly 53% of participants were male, 58% were White, and average baseline BMI was around 33.
All participants were living with type 2 diabetes and had newly initiated either a GLP-1 receptor agonist or a DPP-4 inhibitor between 2015 and 2022. Dulaglutide (Trulicity), semaglutide and liraglutide (Victoza) together accounted for 91% of index prescriptions in the GLP-1 group. Exclusion criteria included fractures resulting from high-energy trauma, as well as osteoporosis and osteopenia.
Where the protective association held – and where it did not
In subgroup analyses, the lower fracture risk was consistent across age groups, across sexes and across levels of frailty.
A separate matched cohort, however, evaluated participants according to diabetes status and produced a notably different picture. Among adults living with type 2 diabetes, GLP-1 use retained a protective association (three-year HR 0.91, 95% CI 0.88–0.95). Among adults without diabetes, it was associated with an increased fracture risk (HR 1.13, 95% CI 1.04–1.23, P<0.001 for interaction).
Consequently, the authors emphasised that the findings cannot be generalised to younger people using GLP-1 medications solely for weight management, nor to those with known osteoporosis or a previous fragility fracture, who were excluded from the study altogether.
What this means for practice
Overall, “the findings do not argue against GLP-1 RA use on the basis of fracture risk, though bone health monitoring remains prudent,” according to the researchers.
They called for prospective randomised trials to evaluate the associations observed, including among people with osteopenia or early osteoporosis, alongside preclinical work to understand the potential mechanisms involved.
CCH insight
For healthcare professionals, this study is a useful reminder that the skeletal consequences of GLP-1 treatment are not yet settled science – and that the answer appears to differ depending on who is being treated and why. Interpreting findings of this kind with confidence depends on a firm grasp of how these medications act in the first place, from gut hormones and appetite regulation through to their wider effects beyond glycaemic control. That is exactly what CCH’s GLP-1RAs in Focus – Why Drugs Like Ozempic Work CPD short course (2 CPD hours, fully online, CPD-accredited) is built to provide, giving clinicians a clear grounding in the mechanisms behind these therapies and the ability to appraise emerging evidence critically, whether or not they prescribe.
Read More
Ozempic and Mounjaro Linked to Modest Rise in Hair Loss Risk, BMJ Study Finds
Key Takeaways:
- Adults living with type 2 diabetes taking GLP-1 receptor agonists developed alopecia more often than those taking SGLT-2 inhibitors (37% higher risk) or DPP-4 inhibitors (68% higher risk), a BMJ study reports.
- Absolute risk stayed low, at 6.91 cases per 1,000 person years for GLP-1 receptor agonists against 5.04 for SGLT-2 inhibitors and 3.89 for DPP-4 inhibitors.
- The association was confined to non-scarring alopecia, where the follicle stays intact and regrowth remains possible.
A modest signal, but one worth discussing in the consultation
Medications from the GLP-1 receptor agonist class, now widely used in the management of type 2 diabetes and obesity, may be associated with a modest increase in hair loss. The finding comes from a study published by The BMJ on 22 July 2026.
The class includes semaglutide, marketed under brand names such as Ozempic and Wegovy, and tirzepatide, marketed as Mounjaro and Zepbound. Researchers found that adults living with type 2 diabetes who were treated with GLP-1 receptor agonists went on to develop alopecia more frequently than people prescribed two other commonly used classes of diabetes medication.
Although the relative increase was significant, the researchers emphasised that the absolute risk of hair loss remained low. Even so, awareness of the possible adverse effect could help people and their clinicians reach better informed treatment decisions together.
Reports of hair loss with semaglutide and tirzepatide
Hair loss has been reported before as a possible adverse effect of GLP-1 receptor agonists, particularly with medications containing semaglutide or tirzepatide. What has been missing is research that directly compares the risk among people taking these medicines with the risk among people taking alternative diabetes treatments.
To address that gap, the research team analysed electronic health records from the University of Pennsylvania Health System (Penn Medicine). They compared rates of alopecia among adults living with type 2 diabetes who began treatment with GLP-1 receptor agonists, SGLT-2 inhibitors or DPP-4 inhibitors.
The analysis covered people treated between January 2019 and September 2024. One comparison included 12,004 people taking GLP-1 receptor agonists and 15,221 taking SGLT-2 inhibitors. A second, separate comparison included 11,964 people taking GLP-1 receptor agonists and 11,233 taking DPP-4 inhibitors.
Accounting for differences between the treatment groups
The groups differed in several important respects before the researchers adjusted their results.
Compared with people taking SGLT-2 inhibitors, those taking GLP-1 receptor agonists were younger (mean age 58 v 65), had a higher body mass index (36.2 v 32.3), and had lower rates of cardiovascular disease and chronic kidney disease.
A similar pattern was seen in the comparison with DPP-4 inhibitors. People taking GLP-1 receptor agonists were again younger (mean age 58 v 67) and had a higher body mass index (36.2 v 31.3).
To limit the influence of these imbalances, the researchers adjusted for factors that might otherwise have shaped the findings, including age, sex, ethnicity, pre-existing conditions, use of other medications, and body mass index.
Higher rates of alopecia after adjustment
Once those adjustments were made, use of a GLP-1 receptor agonist was associated with a 37% higher risk of alopecia than use of an SGLT-2 inhibitor (6.91 v 5.04 per 1,000 person years).
The difference was larger in the second comparison. Risk was 68% higher among people taking GLP-1 receptor agonists than among those taking DPP-4 inhibitors (6.53 v 3.89 per 1,000 person years).
Further analysis indicated that the association was limited to non-scarring alopecia, the form in which hair follicles remain intact and the potential for regrowth is preserved. For this type of hair loss, risk was 53% higher among people taking GLP-1 receptor agonists than among those taking SGLT-2 inhibitors, and 72% higher than among those taking DPP-4 inhibitors.
Why rapid weight loss might disturb the hair cycle
The study did not establish why GLP-1 medications might be connected to hair loss, but the authors set out several plausible explanations.
Rapid weight loss is a well established cause of increased hair shedding. It may also contribute to iron or zinc deficiency, either of which can interfere with the normal hair growth cycle. Hormonal changes related to weight loss or to treatment itself could play a part as well, although further research will be needed to identify the mechanisms at work.
Important questions that remain open
The researchers acknowledged a number of limitations. The available clinical records did not contain enough detail to determine the severity, extent or duration of the alopecia. Nor could the team assess whether hair grew back after people stopped taking the medication.
Because the study was observational, it cannot demonstrate that GLP-1 medications directly caused the hair loss. Other factors that were not measured may have influenced the results.
Set against that, the authors described their work as rigorous, drawing on high quality data from a large and representative group of patients. The findings also held up across additional analyses, which supports their reliability.
What the findings mean for practice
For clinicians, the practical value of a study like this lies less in the headline percentages than in what it adds to the conversation before and during treatment. Anticipating adverse effects, recognising them early and folding them into shared decision-making are core parts of the GLP-1 consultation – the ground covered by CPD courses such as the College of Contemporary Health’s GLP-1RAs in Practice: How to Safely Prescribe Ozempic, Wegovy & Mounjaro, which works through initiation, titration and the avoidance of adverse reactions.
The researchers concluded: “Our findings extend previous anecdotal safety signals and provide more systematic evidence to inform clinical awareness of this potential adverse effect.”
CCH insight
This may seem like an odd perspective, but this could be a good thing if it means that people considering taking GLP-1 medications for vanity reasons (to slim down to their perfect weight when they do not have obesity or type 2 diabetes) are put off, leaving better availability for those who genuinely need it. I am sure that for most people living with obesity or diabetes, a small increased risk of alopecia is worth taking when balanced against the huge health benefits that these drugs usually bring.
Hair loss is unlikely to change prescribing decisions on its own, but it is exactly the kind of adverse effect that patients notice, worry about and sometimes stop treatment over. Knowing how to raise it, put the absolute risk in context and respond if it appears is part of delivering GLP-1 therapy well. CCH’s GLP-1RAs in Practice: How to Safely Prescribe Ozempic, Wegovy & Mounjaro (Or Any Other Weight Loss Drug) is a two-hour, CPD-accredited online course covering every stage of the consultation, from patient selection and titration through to managing adverse reactions, grounded in current NICE guidance and the ADA 2026 Standards of Care.
Find out more about GLP-1RAs in Practice →
Read More
Study Identifies Which Patients With Obesity Respond Best to GLP-1-Based Treatment
Key Takeaways:
- A Mayo Clinic study has identified a distinct biological subtype of obesity – a form of the “hungry gut” phenotype – that responds especially well to tirzepatide.
- People in this subgroup lost an average of 21.5% of their body weight after six months on tirzepatide, roughly double the 11.7% seen in other subtypes.
- The lower appetite-hormone levels traced back to reduced hormone production in the intestine rather than differences in the gut microbiome.
A step towards precision medicine for obesity
Why do some people lose a substantial amount of weight on GLP-1-based medications while others see far more modest results? A new Mayo Clinic study offers a potential answer, identifying a distinct biological subtype of obesity that responds especially well to tirzepatide – a medication that mimics two naturally occurring hormones involved in appetite and blood sugar regulation. The finding moves the field a step closer to precision medicine for obesity, where treatment is matched to an individual’s underlying biology rather than applied uniformly.
The research, published in the journal Gastroenterology, points to a future in which clinicians could predict, rather than simply hope, that a given therapy will work for a given person.
What the researchers found
The team studied 483 adults living with obesity and identified three distinct biological types of the disease. About one in four participants produced lower levels of GLP-1 and other hormones that help people feel full after eating.
This subgroup saw markedly better results on treatment. Patients in this group lost an average of 21.5% of their body weight after six months of tirzepatide, compared with 11.7% for patients in the other groups – losing nearly twice as much weight over the same period.
“Obesity is a complex disease driven by different biological mechanisms,” says senior author Andres Acosta, M.D., Ph.D., a gastroenterologist and the Delaney Family Director of the Nutrition Obesity Research Program at Mayo Clinic in Minnesota. “Our findings suggest we can begin identifying which patients are most likely to respond to specific therapies rather than treating obesity as a single disease.”
Understanding the “hungry gut” subtype
The subgroup that responded so strongly to tirzepatide shares a recognisable biological signature: people in this group produce lower levels of natural appetite-regulating hormones, experience faster stomach emptying and report greater hunger after meals.
Researchers describe this as a form of the “hungry gut” obesity phenotype, which is characterised by an abnormal duration of fullness. Rather than eating unusually large amounts at any one sitting, people with hungry-gut obesity may eat normal portion sizes but find themselves snacking more frequently, because the sense of fullness does not last as long as it should.
Because tirzepatide acts on the same appetite pathways that are underactive in this group, it appears especially well suited to addressing the biology that drives their eating patterns.
Why the underlying biology matters
The study also sheds light on why hormone levels differ in this subgroup. The researchers found that the reduced hormone levels were associated with decreased hormone production in the intestine itself, rather than with differences in the gut microbiome. That distinction offers new insight into the biology underlying this subtype and helps explain where the difference in treatment response originates.
Identifying the right therapy sooner could carry significant long-term benefits. Because obesity increases the risk of diabetes, heart disease, certain cancers and many other serious chronic conditions, matching people to the treatment most likely to help them – rather than relying on a one-size-fits-all approach – could improve long-term health outcomes.
What this means for clinical practice
The findings support growing efforts to personalise obesity treatment based on an individual’s biology. For clinicians, interpreting studies like this one increasingly depends on a firm grasp of how GLP-1-based medications act on appetite hormones and gastric emptying in the first place – the kind of grounding offered by CPD courses such as the College of Contemporary Health’s GLP-1RAs in Focus, which examines why some people respond more strongly to these treatments than others. Still, the authors are careful to note the limits of the current work. They caution that prospective studies are needed before this approach can be incorporated into routine clinical practice.
Even so, the results represent an important step towards more precise, individualised treatment for obesity – and towards a future in which people are guided to the therapy most likely to work for them from the outset.
Studies like this one land almost weekly, and making sense of them starts with understanding how GLP-1 receptor agonists actually work – from gut hormones and appetite regulation to why some people respond far more strongly than others. CCH’s GLP-1RAs in Focus – Why Drugs Like Ozempic Work is a two-hour, CPD-accredited online course created by Prof. Mike Bewick and Nigel Hinchliffe that builds exactly this foundation, whether or not you prescribe. Explore the course and interpret the next headline with confidence.
Source: Mayo Clinic
Read More